These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 25867272)

  • 1. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
    Algazi AP; Cha E; Ortiz-Urda SM; McCalmont T; Bastian BC; Hwang J; Pampaloni MH; Behr S; Chong K; Cortez B; Quiroz A; Coakley F; Liu S; Daud AI
    Br J Cancer; 2015 Apr; 112(8):1326-31. PubMed ID: 25867272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
    Kozloff MF; Martin LP; Krzakowski M; Samuel TA; Rado TA; Arriola E; De Castro Carpeño J; Herbst RS; Tarazi J; Kim S; Rosbrook B; Tortorici M; Olszanski AJ; Cohen RB
    Br J Cancer; 2012 Oct; 107(8):1277-85. PubMed ID: 22990652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.
    Bruce JY; Scully PC; Carmichael LL; Eickhoff JC; Perlman SB; Kolesar JM; Heideman JL; Jeraj R; Liu G
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):187-95. PubMed ID: 26021741
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Scarpelli M; Bruce JY; Carmichael L; Eickhoff J; Kolesar J; Perlman S; Jeraj R; Liu G
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1245-1252. PubMed ID: 27817059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.
    Hoh CK; Burris HA; Bendell JC; Tarazi J; Rosbrook B; Kim S; Infante JR; Reid TR
    Br J Cancer; 2014 Feb; 110(4):875-81. PubMed ID: 24423921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
    Bhatty M; Kato S; Piha-Paul SA; Naing A; Subbiah V; Huang HJ; Karp DD; Tsimberidou AM; Zinner RG; Hwu WJ; Javle M; Patel SP; Hu MI; Varadhachary GR; Conley AP; Ramzanali NM; Holley VR; Kurzrock R; Meric-Bernstam F; Kwang Chae Y; Kim KB; Falchook GS; Janku F
    Cancer; 2019 Feb; 125(3):463-472. PubMed ID: 30383888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
    Twelves C; Chmielowska E; Havel L; Popat S; Swieboda-Sadlej A; Sawrycki P; Bycott P; Ingrosso A; Kim S; Williams JA; Chen C; Olszanski AJ; de Besi P; Schiller JH
    Ann Oncol; 2014 Jan; 25(1):132-8. PubMed ID: 24356624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
    Bondarenko IM; Ingrosso A; Bycott P; Kim S; Cebotaru CL
    BMC Cancer; 2015 May; 15():339. PubMed ID: 25929582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
    Urbonas V; Schadendorf D; Zimmer L; Danson S; Marshall E; Corrie P; Wheater M; Plummer E; Mauch C; Scudder C; Goff M; Love SB; Mohammed SB; Middleton MR
    Ann Oncol; 2019 Feb; 30(2):317-324. PubMed ID: 30428063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
    Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV
    Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
    Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
    Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
    Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
    Martin LP; Kozloff MF; Herbst RS; Samuel TA; Kim S; Rosbrook B; Tortorici M; Chen Y; Tarazi J; Olszanski AJ; Rado T; Starr A; Cohen RB
    Br J Cancer; 2012 Oct; 107(8):1268-76. PubMed ID: 22996612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
    Izar B; Sharfman W; Hodi FS; Lawrence D; Flaherty KT; Amaravadi R; Kim KB; Puzanov I; Sosman J; Dummer R; Goldinger SM; Lam L; Kakar S; Tang Z; Krieter O; McDermott DF; Atkins MB
    Cancer Med; 2017 Aug; 6(8):1904-1914. PubMed ID: 28719152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.